Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice

Psychoneuroendocrinology

Volumn 33, Issue 1, 2008, Pages 54-67

  Steiner, Michel A ^a,b,d   Marsicano, Giovanni ^b,c   Nestler, Eric J ^d   Holsboer, Florian ^a   Lutz, Beat ^b   Wotjak, Carsten T ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c INSERM   (France)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

CB1; Corticosterone; Depression; Desipramine; Forced swim test; HPA axis; SR141716; Stress

Indexed keywords

CANNABINOID 1 RECEPTOR; CORTICOSTERONE; DESIPRAMINE; RIMONABANT;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIORAL STRESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; FORCED SWIMMING TEST; HORMONE RELEASE; MALE; MOUSE; NEUROENDOCRINE SYSTEM; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADAPTATION, PSYCHOLOGICAL; ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CORTICOSTERONE; DEPRESSION; DESIPRAMINE; DISEASE MODELS, ANIMAL; FEMALE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC; STRESS, PSYCHOLOGICAL; SWIMMING; TIME FACTORS;

EID: 37549022284     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2007.09.008     Document Type: Article

References (41)

1. Barna I., Zelena D., Arszovszki A.C., and Ledent C. The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. Life Sci. 75 (2004) 2959-2970
2. Bortolato, M., Manqieri, R.A., Fu, J., Kim, J.H., Arquello, O., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Piomelli, D., 2007. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol. Psychiatry, epub ahead of print; doi:10.1016/J.biopsych.2006.12.001.
3. Buckley N.E., Hansson S., Harta G., and Mezey E. Expression of the CB1 and CB2 receptor messenger RNAs during embryonic development in the rat. Neuroscience 82 (1998) 1131-1149
4. Chevaleyre V., Takahashi K.A., and Castillo P.E. Endocannabinoid-mediated synaptic plasticity in the CNS. Annu. Rev. Neurosci. 29 (2006) 37-76
5. Conti A.C., Cryan J.F., Dalvi A., Lucki I., and Blendy J.A. cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J. Neurosci. 22 (2002) 3262-3268
6. Cota D., Marsicano G., Lutz B., Vicennati V., Stalla G.K., Pasquali R., and Pagotto U. Endogenous cannabinoid system as a modulator of food intake. Int. J. Obesity 27 (2003) 289-301
7. Cota D., Steiner M.A., Marsicano G., Cervino C., Herman J.P., Grubler Y., Stalla J., Pasquali R., Lutz B., Stalla G.K., and Pagotto U. Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology 148 (2007) 1574-1581
8. Cryan J.F., and Holmes A. Advances in modelling human depression and anxiety. Nat. Rev. Drug Discov. 4 (2005) 775-790
9. De Kloet E.R., Joels M., and Holsboer F. Stress and the brain: from adaptation to disease. Nat. Rev. Neurosci. 6 (2005) 463-475
10. Fride E., Suris R., Weidenfeld J., and Mechoulam R. Differential response to acute and repeated stress in cannabinoid CB1 receptor knockout newborn and adult mice. Behav. Pharmacol. 16 (2005) 431-440
11. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., Bouaboula M., Shire D., Lefur G., and Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232 (1995) 54-61
12. Gobbi G., Bambico F.R., Mangieri R., Bortolato M., Campolongo P., Solinas M., Cassano T., Morgese M.G., Debonnel G., Duranti A., Tontini A., Tarzia G., Mor M., Trezza V., Goldberg S.R., Cuomo V., and Piomelli D. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc. Natl. Acad. Sci. USA 102 (2005) 18620-18625
13. Gobshtis N., Ben Shabat S., and Fride E. Antidepressant-induced undesirable weight gain: prevention with rimonabant without interference with behavioral effectiveness. Eur. J. Pharmacol. 554 (2007) 155-163
14. Gold P.W., and Chrousos G.P. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol. Psychiatry 7 (2002) 254-275
15. Griebel G., Stemmelin J., and Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol. Psychiatry 57 (2005) 261-267
16. Haller J., Bakos N., Szirmay M., Ledent C., and Freund T.F. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur. J. Neurosci. 16 (2002) 1395-1398
17. Haller J., Varga B., Ledent C., Barna I., and Freund T.F. Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur. J. Neurosci. 19 (2004) 1906-1912
18. Hill M.N., and Gorzalka B.B. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?. Behav. Pharmacol. 16 (2005) 333-352
19. Hill M.N., and Gorzalka B.B. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur. Neuropsychopharmacol. 15 (2005) 593-599
20. Hill M.N., Ho W.S., Sinopoli K.J., Viau V., Hillard C.J., and Gorzalka B.B. Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 31 (2006) 2591-2599
21. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23 (2000) 477-501
22. Ising M., Horstmann S., Kloiber S., Lucae S., Binder E.B., Kern N., Kunzel H.E., Pfennig A., Uhr M., and Holsboer F. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression-a potential biomarker?. Biol. Psychiatry 62 (2007) 47-54
23. Karanth S., Linthorst A.C.E., Stalla G.K., Barden N., Holsboer F., and Reul J.M.H.M. Hypothalamic-pituitary-adrenocortical axis changes in a transgenic mouse with impaired glucocorticoid receptor function. Endocrinology 138 (1997) 3476-3485
24. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb. Exp. Pharmacol. 168 (2005) 299-325
25. Manzanares J., Corchero J., and Fuentes J.A. Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of Delta(9)-tetrahydrocannabinol in rats. Brain Res. 839 (1999) 173-179
26. Marsicano G., and Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur. J. Neurosci. 11 (1999) 4213-4225
27. Marsicano G., and Lutz B. Neuromodulatory functions of the endocannabinoid system. J. Endocrinol. Invest. 29 (2006) 27-46
28. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., Hermann H., Tang J.R., Hofmann C., Zieglgansberger W., Di Marzo V., and Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Nature 418 (2002) 530-534
29. Pagotto U., Marsicano G., Fezza F., Theodoropoulou M., Grubler Y., Stalla J., Arzberger T., Milone A., Losa M., Di Marzo V., Lutz B., and Stalla G.K. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J. Clin. Endocrinol. Metab. 86 (2001) 2687-2696
30. Pagotto U., Marsicano G., Cota D., Lutz B., and Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr. Rev. 27 (2006) 73-100
31. Patel S., Roelke C.T., Rademacher D.J., Cullinan W.E., and Hillard C.J. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145 (2004) 5431-5438
32. Shearman L.P., Rosko K.M., Fleischer R., Wang J., Xu S., Tong X.S., and Rocha B.A. Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav. Pharmacol. 14 (2003) 573-582
33. Steiner, M.A., Wanisch, K., Monory, K., Marsicano, G., Borroni, E., Bächli, H., Holsboer, F., Lutz, B., Wotjak, C.T., 2007. Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice. Pharmacogenom. J., epub ahead of print; doi:10.1038/sj.tpj.6500466.
34. Tzavara E.T., Davis R.J., Perry K.W., Li X., Salhoff C., Bymaster F.P., Witkin J.M., and Nomikos G.G. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br. J. Pharmacol. 138 (2003) 544-553
35. Uriguen L., Perez-Rial S., Ledent C., Palomo T., and Manzanares J. Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 46 (2004) 966-973
36. Valenti M., Vigano D., Casico M.G., Rubino T., Steardo L., Parolaro D., and Di Marzo V. Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. Cell. Mol. Life Sci. 61 (2004) 945-950
37. Wade M.R., Degroot A., and Nomikos G.G. Cannabinoid CB1 receptor antagonism modulates plasma corticosterone in rodents. Eur. J. Pharmacol. 551 (2006) 162-167
38. Wei Q., Lu X.Y., Liu L., Schafer G., Shieh K.R., Burke S., Robinson T.E., Watson S.J., Seasholtz A.F., and Akil H. Glucocorticoid receptor overexpression in forebrain: a mouse model of increased emotional lability. Proc. Natl. Acad. Sci. USA 101 (2004) 11851-11856
39. Wenger T., Fernandez-Ruiz J.J., and Ramos J.A. Immunocytochemical demonstration of CB1 cannabinoid receptors in the anterior lobe of the pituitary gland. J. Neuroendocrinol. 11 (1999) 873-878
40. Wenger T., Ledent C., and Tramu G. The endogenous cannabinoid, anandamide, activates the hypothalamo-pituitary-adrenal axis in CB1 cannabinoid receptor knockout mice. Neuroendocrinology 78 (2003) 294-300
41. Witkin J.M., Tzavara E.T., Davis R.J., Li X., and Nomikos G.G. A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. Trends Pharmacol. Sci. 26 (2005) 609-617